A Phase I/II, Randomized, Observer Blinded Study to Evaluate and Compare the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline Biologicals' Investigational Pneumococcal Vaccine Formulations Versus a Licensed Non-GlaxoSmithKline Biologicals' Vaccine and GlaxoSmithKline Biologicals' Aluminum-based 10-valent Pneumococcal Conjugate Vaccine, in Healthy Elderly Subjects

Trial Profile

A Phase I/II, Randomized, Observer Blinded Study to Evaluate and Compare the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline Biologicals' Investigational Pneumococcal Vaccine Formulations Versus a Licensed Non-GlaxoSmithKline Biologicals' Vaccine and GlaxoSmithKline Biologicals' Aluminum-based 10-valent Pneumococcal Conjugate Vaccine, in Healthy Elderly Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2017

At a glance

  • Drugs Pneumococcal 10-valent vaccine conjugate; Pneumococcal 11-valent vaccine conjugate; Pneumococcal vaccine
  • Indications Otitis media; Pneumococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 30 Oct 2008 Actual end date changed from 1 Jun 2007 to 1 Sep 2007 as reported by Clinicaltrials.gov.
    • 30 Oct 2008 Actual start date changed from 1 Jun 2006 to 1 May 2006 as reported by ClinicalTrials.gov.
    • 30 Oct 2008 Actual patient number (335) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top